学术周报 · IF≥10
胃肠外科领域文献阅读汇编
2026年第39周 (2026-09-23) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
| # | 论文 | 期刊 | IF |
|---|---|---|---|
| 1 | CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovar... | Journal for immunotherapy of cancer | IF 11.7 |
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Journal for immunotherapy of cancer | 1 | IF 11.7 |
1卵巢癌/胃癌 (1篇)
基础研究 (1篇)
Ovarian and gastric cancers are associated with poor prognosis and derive limited benefit from current therapies, highlighting the need for novel immunotherapeutic approaches. The L1 cell adhesion molecule (L1CAM) is aberrantly expressed in several types of solid tumors and is associated with aggressive clinical behavior. This study aimed to develop and characterize optimized L1CAM-targeted chimeric antigen receptor-T (CAR-T) cells with improved efficacy and safety, using patient-derived preclinical models of ovarian and gastric cancer. L1CAM expression was assessed in tumor tissues from patients with ovarian cancer (OC;n=227) and gastric cancer (GC;n=132), followed by an analysis of its clinical impact. A panel of L1CAM-targeted CAR constructs incorporating distinct hinge and co-stimulatory domains was systematically evaluated. Functional activity was assessed by cytotoxicity and cytokine release assays using cancer cell lines and patient-derived tumor cells. Antitumor efficacy, persistence, and safety were evaluated in xenograft and patient-derived xenograft (PDX) models, including NanoLuc-based in vivo tracking of CAR-T cell distribution. High L1CAM expression correlated with aggressive clinicopathological features and adverse prognosis in patients with OC. Among the constructs tested, CAR-T cells incorporating an IgD/IgG1 hybrid hinge and dual CD28-ICOS co-stimulatory domains demonstrated the most potent antigen-specific activity. These cells exhibited enhanced cytotoxicity, robust interferon-γ production, and sustained functional activity. In vivo, optimized L1CAM CAR-T cells achieved complete tumor regression in OC PDX models and significant tumor suppression in GC models, with durable tumor control and CAR-T persistence. Intraperitoneal delivery further improved therapeutic efficacy and CAR-T cell localization compared with intravenous administration. Importantly, no evidence of neurotoxicity or systemic toxicity was observed, supporting a favorable safety profile. Optimized L1CAM-targeted CAR-T cells demonstrate potent, durable, and antigen-specific antitumor activity with a favorable safety profile in preclinical models of OC and GC. The combination of rational CAR design (CD28-ICOS signaling) and optimized delivery strategy provides a strong rationale for the clinical development of L1CAM-targeted CAR-T therapy, particularly in patients with L1CAM-positive solid tumors.
中文摘要:卵巢癌和胃癌预后较差,从当前治疗中获益有限,因此亟需新型免疫治疗策略。L1细胞黏附分子(L1CAM)在多种实体瘤中异常表达,并与侵袭性临床行为相关。本研究旨在利用卵巢癌和胃癌的患者来源临床前模型,开发并表征疗效和安全性更优的L1CAM靶向嵌合抗原受体T细胞(CAR-T)。研究评估了卵巢癌(OC;n=227)和胃癌(GC;n=132)患者肿瘤组织中的L1CAM表达,并分析其临床影响。随后系统评估了一组包含不同铰链区和共刺激结构域的L1CAM靶向CAR构建体。使用癌细胞系和患者来源肿瘤细胞,通过细胞毒性和细胞因子释放试验评估功能活性。在异种移植和患者来源异种移植(PDX)模型中评估抗肿瘤疗效、持久性和安全性,包括基于NanoLuc的CAR-T细胞分布体内追踪。高L1CAM表达与OC患者侵袭性临床病理特征和不良预后相关。在测试的构建体中,整合IgD/IgG1混合铰链和双重CD28-ICOS共刺激结构域的CAR-T细胞表现出最强的抗原特异性活性。这些细胞表现出增强的细胞毒性、强劲的干扰素-γ产生和持续的功能活性。在体内,优化的L1CAM CAR-T细胞在OC PDX模型中实现完全肿瘤消退,在GC模型中显著抑制肿瘤,并具有持久的肿瘤控制和CAR-T持久性。与静脉给药相比,腹腔给药进一步提高了治疗效果和CAR-T细胞定位。重要的是,未观察到神经毒性或全身毒性的证据,支持良好的安全性特征。优化的L1CAM靶向CAR-T细胞在OC和GC临床前模型中表现出强效、持久且抗原特异性的抗肿瘤活性,并具有良好的安全性。合理的CAR设计(CD28-ICOS信号传导)与优化给药策略的结合,为L1CAM靶向CAR-T疗法的临床开发提供了强有力的依据,尤其是在L1CAM阳性实体瘤患者中。